Stock Analysis Predicts Strong Buy Opportunity and 84% Gain Potential Following Major Crash
Moderna Inc (WKN: A2N9D9), the biotech company behind the successful development of COVID-19 vaccines, presents a compelling growth opportunity for investors willing to accept some sector risks. This conclusion, however, contrasts with the advice from BÖRSE ONLINE, which advises against buying the shares due to their high volatility and suitability only for very speculative investors.
Recent market estimates suggest a potential upside of approximately 84% for Moderna's stock, indicating strong growth potential. The stock price has shown positive momentum, with daily gains hovering around 5%, and has been among the top performers in the S&P 500 recently.
Key considerations for this buying opportunity include Moderna's market valuation, recent performance, product pipeline, and risks. The company has a market cap of around $10.67 billion and an enterprise value of $5.28 billion, with an EV/Sales ratio for 2025 at 0.63x, which may imply the stock is undervalued relative to sales.
Moderna's stock has experienced a monthly gain of around 5% and daily spikes close to 6%, placing it among the top performers in the S&P 500 recently. The company is advancing its vaccine portfolio, notably seeking clearance for a combined COVID-19 and influenza vaccine, which could drive future revenue growth and market interest.
However, the stock has shown volatility, including a year-to-date decline of over 30%, reflecting sector risks and competitive pressures. Despite the upside, the stock's historical volatility and the evolving vaccine market landscape suggest careful monitoring is advised before investing.
Analyst Edward Tenthoff of Piper Sandler sees an entry opportunity in Moderna's stock. He reaffirmed his 'Outperform' rating for Moderna and set a price target of $69, seeing 84% upside potential for the stock. Tenthoff writes that COVID vaccinations declining, mRESVIA disappointing, and RFK Jr.'s uncertainty make this an attractive long-term entry point for Moderna.
However, the consensus among analysts is more cautious. They see 126% upside potential to $84 for Moderna's stock, but only recommend holding the shares. BÖRSE ONLINE's stance on Moderna Inc (WKN: A2N9D9) contrasts with the consensus estimates, advising against buying the shares due to their risky nature.
Moderna's management has reaffirmed the product revenue forecast of $3 to $3.5 billion in 2024. Despite the stock's recent losses, having returned more than 60% of its value this year, Moderna has returned to profitability through the earlier adaptation of COVID vaccines.
In summary, Moderna's significant upside potential combined with ongoing product developments represents a compelling buying opportunity for investors willing to accept some biotech sector risk. However, the stock's historical volatility and the evolving vaccine market landscape suggest careful monitoring is advised before investing.
Investors who are open to accepting biotech sector risks might find the growth opportunities in Moderna Inc's stock enticing, given its potential upside of approximately 84%. However, due to its high volatility and suitability only for speculative investors, BÖRSE ONLINE advises against buying the shares.
